DiogenX
Serena Silvano's work experience begins with their current role as a Principal Scientist at DiogenX, a position they have held since January 2021. Prior to that, they worked as a LABEX Signalife PhD Student at Université Côte d'Azur from September 2016 to December 2020. Before their PhD, Serena was a Master Thesis Student at Université Côte d'Azur from April 2015 to March 2016. Their earliest work experience was as a Thesis Student at Università degli Studi di Torino from November 2012 to May 2013.
Serena Silvano earned their Bachelor's degree in Biology/Biological Sciences, General from Università degli Studi di Torino from 2010 to 2013. Serena then pursued a Master's Degree in Genetics and molecular biology in basic and biomedical research at Sapienza Università di Roma from 2013 to 2016. Later, Serena Silvano enrolled in Université Côte d'Azur for their Doctor of Philosophy (PhD) in Diabetes Genetics, which they completed from 2016 to 2020. Additionally, in October 2016, Serena Silvano obtained a Laboratory Animal Science Certification from the Centre Méditerranéen de Médecine Moléculaire, UMR INSERM 1065/ UNSA.
This person is not in any teams
DiogenX
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.